New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

Moving patients from considering screening to completing it remains the central challenge in colorectal cancer prevention, Fendrick explained to Patient Care.

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.

The phase 3 REDFINE program showed mean weight loss of 20% at 68 weeks, supporting the dual-mechanism approach that combines semaglutide with cagrilintide.

This is a summary of the multisystem effects of hidradenitis suppurativa followed by practical tips for primary care in recognizing and managing the chronic skin condition.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The VITESSE trial met its primary endpoint, with the VIASKIN Peanut patch improving desensitization versus placebo in peanut-allergic children aged 4 to 7 years.

Physician researcher Fendrick offers an expert perspective on why removing cost barriers matters, and why navigation and patient realities still determine whether CRC screening succeeds.

CDC officials say the shift reflects evidence review and informed consent, as public health groups warn of potential downstream effects.

Phase 2b REZOLVE-AA trial results show rezpegaldesleukin reduced SALT scores versus placebo in severe alopecia areata, supporting Phase 3 development.